Drug intelligence / Profile preview

Whispokyn-1

Development stage: Unknown
Lead developer: Kyntox Biotech
Modality: Small Molecules, Peptides, Recombinant Proteins and Enzymes
Administration: Oral

Overview

Whispokyn-1 is an antibiotic-free aquaculture product developed by Kyntox Biotech for the prevention and management of White Spot Syndrome Virus (WSSV) in shrimp. The formulation is a complex mixture containing organic acids, small molecules, proteins, bioactive peptides, and phyto-constituents. It is designed to enhance the shrimp's innate immune response and provide a protective barrier against viral infection, serving as a sustainable alternative to traditional chemical treatments. The product has received approval from the Coastal Aquaculture Authority (CAA) in India for use in shrimp farming.

Brand names: Whispokyn-1Whispokyn1Whispokyn 1WHISPOKYN Formula-1
Other names: Whispokyn

Beyond the preview

Go deeper on Whispokyn-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Whispokyn-1.

Explore the full profile